Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


First Amendment Challenge Mulled As Amarin Seeks To Unchain ANCHOR Results

Executive Summary

If Amarin can’t get its Vascepa expanded indication through FDA, it could try to get the courts to clarify the scope of free speech protections post-Caronia.


Related Content

Cholesterol Guidelines Look High And Low: Statin Market Extended At Both Ends
FDA Makes It Formal, Rescinds SPA For Amarin’s ANCHOR Study
Cholesterol Drug Approvals May Hinge On Outcomes Studies; FDA Rejects Diabetes-style Tiered Trials
The Consequences of Caronia: Impact On FDA’s Off-Label Regulation


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts